The approval of chimeric antigen receptor T-cell (CAR-T) therapies for relapsed/refractory multiple myeloma (RRMM) has significantly advanced treatment options. Nursing care is essential in CAR-T therapy administration and supporting patients, caregivers, and the broader care team. This study outlines the CAR-T therapy process and practical considerations for nursing professionals, drawing on current literature, guidelines, and insights from experienced nurses. It details the comprehensive role of nurses throughout CAR-T therapy, emphasizing their involvement in patient eligibility assessment, education, and long-term monitoring of associated toxicities.

Effective CAR-T therapy requires collaboration among nursing professionals and other healthcare providers as patients transition between community oncology providers and specialized treatment centers. Nurses are crucial in assessing patient eligibility, educating patients and caregivers, and managing CAR-T–associated toxicities. As eligibility for CAR-T therapy expands, the demand for these treatments is expected to increase. This highlights the need for nurses to thoroughly understand the CAR-T process, associated risks, and their roles at each treatment stage.

Reference: Steinbach M, Zitella LJ, Florendo E, et al. Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma. Semin Oncol Nurs. 2023;39(6):151505. doi: 10.1016/j.soncn.2023.151505.